CA3213726A1 - Formulations de l-asparaginase - Google Patents

Formulations de l-asparaginase Download PDF

Info

Publication number
CA3213726A1
CA3213726A1 CA3213726A CA3213726A CA3213726A1 CA 3213726 A1 CA3213726 A1 CA 3213726A1 CA 3213726 A CA3213726 A CA 3213726A CA 3213726 A CA3213726 A CA 3213726A CA 3213726 A1 CA3213726 A1 CA 3213726A1
Authority
CA
Canada
Prior art keywords
formulation
asparaginase
administered
present disclosure
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3213726A
Other languages
English (en)
Inventor
Sekhar Kanapuram
Haripada MAITY
Guifeng Jiang
Roja NARWAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Ireland Ltd
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of CA3213726A1 publication Critical patent/CA3213726A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des formulations stables, aqueuses et non lyophilisées de L-asparaginase. L'invention concerne également des procédés d'utilisation de telles formulations dans le traitement d'une ou de plusieurs maladies, de troubles ou d'états (par exemple, des cancers tels que la leucémie lymphoblastique aiguë (ALL) ou un lymphome lymphoblastique (LBL)) qui peuvent être traités par déplétion d'asparagine.
CA3213726A 2021-04-06 2022-04-05 Formulations de l-asparaginase Pending CA3213726A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171429P 2021-04-06 2021-04-06
US63/171,429 2021-04-06
PCT/US2022/071562 WO2022217231A1 (fr) 2021-04-06 2022-04-05 Formulations de l-asparaginase

Publications (1)

Publication Number Publication Date
CA3213726A1 true CA3213726A1 (fr) 2022-10-13

Family

ID=81748398

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3213726A Pending CA3213726A1 (fr) 2021-04-06 2022-04-05 Formulations de l-asparaginase

Country Status (12)

Country Link
EP (1) EP4319818A1 (fr)
JP (1) JP2024515555A (fr)
KR (1) KR20230165799A (fr)
CN (1) CN117377494A (fr)
AR (1) AR125301A1 (fr)
AU (1) AU2022256071A1 (fr)
BR (1) BR112023019862A2 (fr)
CA (1) CA3213726A1 (fr)
CL (1) CL2023002983A1 (fr)
CO (1) CO2023014093A2 (fr)
MX (1) MX2023011693A (fr)
WO (1) WO2022217231A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985548B2 (en) 2006-03-03 2011-07-26 The United States Of America As Represented By The Department Of Health And Human Services Materials and methods directed to asparagine synthetase and asparaginase therapies
UA123020C2 (uk) * 2016-06-01 2021-02-03 Сервьє Айпі Юкей Лімітед Склади поліалкіленоксид-аспарагінази та способи їхнього виготовлення й використання
EP4048303A1 (fr) * 2019-10-25 2022-08-31 Jazz Pharmaceuticals Ireland Ltd. L-asparaginase recombinante

Also Published As

Publication number Publication date
JP2024515555A (ja) 2024-04-10
CN117377494A (zh) 2024-01-09
AU2022256071A1 (en) 2023-10-19
MX2023011693A (es) 2023-12-15
CL2023002983A1 (es) 2024-04-12
CO2023014093A2 (es) 2023-10-30
BR112023019862A2 (pt) 2023-11-07
WO2022217231A1 (fr) 2022-10-13
AR125301A1 (es) 2023-07-05
EP4319818A1 (fr) 2024-02-14
KR20230165799A (ko) 2023-12-05

Similar Documents

Publication Publication Date Title
AU2020202407B2 (en) Liquid protein formulations containing viscosity-lowering agents
US20230173042A1 (en) Methods of treatment with asparaginase
ES2476690T3 (es) Moléculas conjugadas del Factor VIII
US20110158987A1 (en) Novel antibody formulation
JP2011511074A (ja) 結腸直腸癌を治療するためのピコプラチンおよびセツキシマブの使用
CA3213726A1 (fr) Formulations de l-asparaginase
US20220323556A1 (en) Dosing and administration of recombinant l-asparaginase
US20240197841A1 (en) Formulations of l-asparaginase
KR20230174239A (ko) 고농도 이중특이성 항체 제제
CN113645988A (zh) 基于fms样酪氨酸激酶3配体(flt3l)的嵌合蛋白
Hegde et al. To market, to market–2006
TWI781415B (zh) 用於皮下注射之包含人類玻尿酸酶ph20變異體及藥物的醫藥組合物
WO2023235847A1 (fr) Compositions d'anticorps et leurs procédés d'utilisation
EP3184149A1 (fr) Glycoprotéine v soluble pour le traitement de maladies thrombotiques
NZ717944B2 (en) Liquid protein formulations containing viscosity-lowering agents
PL203676B1 (pl) Liofilizowany preparat kahalalidu F, zestaw, odtworzony roztwór i zastosowanie